1. Field of the Disclosure
The present disclosure relates generally to a blood transfer device. More particularly, the present disclosure relates to a blood transfer device, a blood transfer and testing system, a lancet and blood transfer device, and a method of loading an anticoagulant.
2. Description of the Related Art
Blood sampling is a common health care procedure involving the withdrawal of at least a drop of blood from a patient. Blood samples are commonly taken from hospitalized, homecare, and emergency room patients either by finger stick, heel stick, or venipuncture. Once collected, blood samples may be analyzed to obtain medically useful information including, for example, chemical composition, hematology, and coagulation.
Blood tests determine the physiological and biochemical states of the patient, such as disease, mineral content, drug effectiveness, and organ function. Blood tests may be performed in a clinical laboratory or at the point-of-care near the patient.
The present disclosure provides a specimen mixing and transfer device adapted to receive a sample. The specimen mixing and transfer device includes a housing, a material including pores that is disposed within the housing, and a dry anticoagulant powder within the pores of the material. In one embodiment, the material is a sponge material. In other embodiments, the material is an open cell foam. In one embodiment, the open cell foam is treated with an anticoagulant to form a dry anticoagulant powder finely distributed throughout the pores of the material. A blood sample may be received within the specimen mixing and transfer device. The blood sample is exposed to and mixes with the anticoagulant powder while passing through the material.
A specimen mixing and transfer device of the present disclosure offers uniform and passive blood mixing with an anticoagulant under flow-through conditions. A specimen mixing and transfer device of the present disclosure could catch blood clots or other contaminants within the microstructure of the material and prevent them from being dispensed into a diagnostic sample port. A specimen mixing and transfer device of the present disclosure enables a simple, low-cost design for passive flow-through blood stabilization. A specimen mixing and transfer device of the present disclosure enables precisely controlled loading of an anticoagulant into the material by soaking it with an anticoagulant and water solution and then drying the material to form a finely distributed dry anticoagulant powder throughout the pores of the material.
A specimen mixing and transfer device of the present disclosure may provide an effective passive blood mixing solution for applications wherein blood flows through a line. Such a specimen mixing and transfer device is useful for small blood volumes, e.g., less than 50 μL or less than 500 μL, and/or where inertial, e.g., gravity based, forces are ineffective for bulk manual mixing by flipping back and forth a blood collection container such as is required for vacuum tubes.
In accordance with an embodiment of the present invention, a specimen mixing and transfer device adapted to receive a sample includes a housing having a first end, a second end, and a sidewall extending therebetween; a material including pores and disposed within the housing; and a dry anticoagulant powder within the pores of the material.
In one configuration, the sample is a blood sample. In another configuration, the housing is adapted to receive the blood sample therein via the first end. In yet another configuration, with the blood sample received within the housing, the blood sample passes through the material thereby effectively mixing the blood sample with the dry anticoagulant powder. In one configuration, the blood sample dissolves and mixes with the dry anticoagulant powder while passing through the material. In another configuration, the material is an open cell foam. In yet another configuration, the material is a sponge. In one configuration, the first end includes an inlet. In another configuration, the second end includes an outlet. In yet another configuration, the housing defines a mixing chamber having a material including pores disposed within the mixing chamber. In one configuration, the housing includes an inlet channel in fluid communication with the inlet and the mixing chamber and an outlet channel in fluid communication with the mixing chamber and the outlet. In another configuration, the housing includes a dispensing chamber between the mixing chamber and the outlet.
In accordance with another embodiment of the present invention, a specimen mixing and transfer device adapted to receive a sample includes a housing having a first end, a second end, and a sidewall extending therebetween; a dry anticoagulant powder disposed within the housing; and a mixing element disposed within the housing.
In one configuration, the sample is a blood sample. In another configuration, the housing is adapted to receive the blood sample therein via the first end. In yet another configuration, with the blood sample received within the housing, the mixing element interferes with a flow of the blood sample to promote mixing of the blood sample with the dry anticoagulant powder. In one configuration, the dry anticoagulant powder is deposited on an interior surface of the housing. In another configuration, the mixing element comprises a plurality of posts. In one configuration, the first end includes an inlet. In another configuration, the second end includes an outlet. In yet another configuration, the housing defines a mixing chamber having a dry anticoagulant powder disposed within the mixing chamber. In one configuration, the housing includes an inlet channel in fluid communication with the inlet and the mixing chamber and an outlet channel in fluid communication with the mixing chamber and the outlet. In another configuration, the housing includes a dispensing chamber between the mixing chamber and the outlet. In yet another configuration, the housing includes two diverted flow channels between the inlet channel and the outlet channel.
In accordance with yet another embodiment of the present invention, a method of loading an anticoagulant to a material having pores includes soaking the material in a liquid solution of the anticoagulant and water; evaporating the water of the liquid solution; and forming a dry anticoagulant powder within the pores of the material.
In one configuration, the material is a sponge. In another configuration, the material is an open cell foam.
The above-mentioned and other features and advantages of this disclosure, and the manner of attaining them, will become more apparent and the disclosure itself will be better understood by reference to the following descriptions of embodiments of the disclosure taken in conjunction with the accompanying drawings, wherein:
Corresponding reference characters indicate corresponding parts throughout the several views. The exemplifications set out herein illustrate exemplary embodiments of the disclosure, and such exemplifications are not to be construed as limiting the scope of the disclosure in any manner.
The following description is provided to enable those skilled in the art to make and use the described embodiments contemplated for carrying out the invention. Various modifications, equivalents, variations, and alternatives, however, will remain readily apparent to those skilled in the art. Any and all such modifications, variations, equivalents, and alternatives are intended to fall within the spirit and scope of the present invention.
For purposes of the description hereinafter, the terms “upper”, “lower”, “right”, “left”, “vertical”, “horizontal”, “top”, “bottom”, “lateral”, “longitudinal”, and derivatives thereof shall relate to the invention as it is oriented in the drawing figures. However, it is to be understood that the invention may assume various alternative variations, except where expressly specified to the contrary. It is also to be understood that the specific devices illustrated in the attached drawings, and described in the following specification, are simply exemplary embodiments of the invention. Hence, specific dimensions and other physical characteristics related to the embodiments disclosed herein are not to be considered as limiting.
With a sample 12 received within the specimen mixing and transfer device 10, a portion of the specimen mixing and transfer device 10 acts as a flow-through chamber for the effective mixing of a sample 12 with the dry anticoagulant powder 20 within the material 16. In other embodiments, the material 16 may contain other dry substances. The effective mixing is achieved by passing the sample 12 through the material 16 having the dry anticoagulant powder 20 distributed throughout its microstructure.
A specimen mixing and transfer device 10 of the present disclosure offers uniform and passive blood mixing with an anticoagulant under flow-through conditions. A specimen mixing and transfer device 10 of the present disclosure may catch blood clots or other contaminants within the microstructure of the material 16 and prevent them from being dispensed into a diagnostic sample port. A specimen mixing and transfer device 10 of the present disclosure enables a simple, low cost design for passive flow-through blood stabilization. A specimen mixing and transfer device 10 of the present disclosure enables precisely controlled loading of an anticoagulant into the material 16 by soaking it with an anticoagulant and water solution and then drying the material 16 to form a finely distributed dry anticoagulant powder 20 throughout the pores 18 of the material 16.
A specimen mixing and transfer device 10 of the present disclosure may provide an effective passive blood mixing solution for applications wherein blood flows through a line. Such a specimen mixing and transfer device 10 is useful for small blood volumes, e.g., less than 50 μL, or less than 500 μL, and/or where inertial, e.g., gravity based, forces are ineffective for bulk manual mixing by flipping back and forth a blood collection container such as is required for vacuum tubes.
Referring to
In one embodiment, the material 16 is a sponge material. In other embodiments, the material 16 is an open cell foam. In one embodiment, the open cell foam is treated with an anticoagulant, as described in detail below, to form a dry anticoagulant powder 20 finely distributed throughout the pores 18 of the material 16. A sample 12 may be received within the specimen mixing and transfer device 10. In some embodiments, the sample 12 gets soaked into the material 16 based on capillary principles. In some embodiments, the sample 12 may be a blood sample. The blood sample is exposed to and mixes with the anticoagulant powder 20 while passing through the intricate microstructure of the material 16. In this manner, the specimen mixing and transfer device 10 produces a stabilized sample. In some embodiments, the stabilized sample may be transferred to a diagnostic instrument such as a blood testing device, a point-of-care testing device, or similar analytical device.
In one embodiment, the material 16 is an open cell foam. For example, the material 16 is a soft deformable open cell foam that is inert to blood. In one embodiment, the open cell foam may be a melamine foam, such as Basotect® foam commercially available from BASF. In another embodiment, the open cell foam may consist of a formaldehyde-melamine-sodium bisulfite copolymer. The open cell foam may be a flexible, hydrophilic open cell foam that is resistant to heat and many organic solvents. In one embodiment, the open cell foam may be a sponge material.
A method of loading an anticoagulant to a material 16 having pores 18 will now be discussed. In one embodiment, the method includes soaking the material 16 in a liquid solution of the anticoagulant and water; evaporating the water of the liquid solution; and forming a dry anticoagulant powder 20 within the pores 18 of the material 16.
The method of the present disclosure enables precisely controlled loading of an anticoagulant into the material 16 by soaking it with an anticoagulant and water solution and then drying the material 16 to form a finely distributed dry anticoagulant powder 20 throughout the pores 18 of the material 16, as shown in
Anticoagulants such as Heparin or EDTA (Ethylene Diamine Tetra Acetic Acid), as well as other blood stabilization agents, could be introduced into the material 16 as a liquid solution by soaking the material 16 in the liquid solution of a desired concentration. After evaporating the liquid phase, e.g., evaporating the water from a water and Heparin solution, a dry anticoagulant powder 20 is formed and finely distributed throughout the internal structure of the material 16, as shown in
In one configuration, a key advantage of providing an open cell foam as the material 16 is that a known amount of anticoagulant may be loaded into the pores 18 of the foam material. A desired concentration of an anticoagulant may be dissolved in water or other suitable solvent and then introduced into the pores 18 of the open cell foam material 16 in liquid form. In one embodiment, the anticoagulant may be loaded into the pores 18 by dipping the open cell foam material 16 into a solution of anticoagulant and water or solvent and subsequently allowing the open cell foam material 16 to dry. The open cell foam material 16 may be allowed to dry in ambient air or in a heated oven. After drying, the anticoagulant may be distributed throughout the internal microstructure of the open cell foam material 16 in the form of a dry powder.
It is noted that suitable hydrophilic foam material having interconnected cell pores may be loaded with anticoagulant, as described above, and used as described herein for flow-through blood stabilization.
One key advantage of using a melamine-based open cell foam material is that melamine foams have a generally low analyte bias. As discussed herein, analyte bias is the difference in a measured value of an analyte as compared to a blood control value. Generally, analyte bias occurs when analytes adhere to a surface of a material, when analytes are leached from a material, via introduction of other components which may interfere with a measurement, or upon activation of a biological process. Additional open cell foam materials which are suitable for use as described herein include organic thermoplastic and thermosetting polymers and co-polymers, including but not limited to polyolefins, polyimides, polyamides, such as polyethylene terephthalate (PET), polypropylene (PP), polyethylene (PE), and the like. The material may be in fibrous structure, such as woven or random fiber form, or irregular 3D structure.
In order to avoid or minimize potential analyte bias associated with the housing 14 of the transfer device 10, the material of the housing 14 may be treated. In one embodiment, the housing 14 may be treated with an additive coating which acts to block analytes from sticking to a surface. Additive coatings may include, but are not limited to, 1.) proteins, such as bovine serum albumin (BSA), casein, or non-fat milk, 2.) surfactants such as polysorbate 20 (Tween 20) and organosilicone (L-720), 3.) polymers and copolymers such as polyethylene glycol (PEG), polyvinyl alcohol (PVA), and polyvinylpyrrolidone (PVP), 4.) carbohydrates such as destran and glycosamino glycans, such as heparin, and 5.) cell membrane mimicking polymers such as Lipidure.
Alternatively, the housing 14 may be treated with a chemical surface modification. Chemical surface modifications can include, but are not limited to, 1.) gas plasma treatment, 2.) chemical bonding or polyethylene glycol (PEG) or other polymers to achieve a desired hydrophobicity or hydrophilicity, 3.) chemical modification of the surface to include hydrophilic compositions such as ethylene glycol, or hydrophobic groups, such as long carbon chains, and 4.) vapor deposition of a substance, such as parylene. It is appreciated herein that combinations of any of the above materials may be used to achieve the desired properties to minimize analyte bias for a specific analyte or group of analytes.
In one embodiment, the mixing chamber 36 includes the material 16 having a dry anticoagulant powder 20 therein. For example, referring to
Referring to
With the sample 12 received within the mixing chamber 36, the mixing chamber 36 acts as a flow-through chamber for the effective mixing of a sample 12 with the dry anticoagulant powder 20 within the material 16. In other embodiments, the material 16 may contain other dry substances. The effective mixing is achieved by passing the sample 12 through the material 16 having the dry anticoagulant powder 20 distributed throughout its microstructure. The sample 12 dissolves and mixes with the dry anticoagulant powder 20 while passing through the material 16.
Referring to
Referring to
After the blood sample is exposed to and mixes with the anticoagulant powder 20 while passing through the intricate microstructure of the material 16, a stabilized sample flows from the material 16 to the dispensing chamber 38 via the outlet channel 34. The stabilized sample can remain within the dispensing chamber 38 until it is desired to transfer the stabilized sample from the specimen mixing and transfer device 10. For example, the stabilized sample may be transferred to a diagnostic instrument such as a blood testing device, a point-of-care testing device, or similar analytical device.
The housing 114 includes a first end 122, a second end 124, and a sidewall 126 extending between the first end 122 and the second end 124. In one embodiment, the first end 122 includes an inlet 128 and the second end 124 includes an outlet 130.
Referring to
In one embodiment, the inlet channel 132 and the outlet channel 134 are in fluid communication via a first flow channel 140 and a second flow channel 142. For example, the inlet channel 132 may branch off into two separate flow channels, e.g., the first flow channel 140 and the second flow channel 142. The two separate flow channels, e.g., the first flow channel 140 and the second flow channel 142, may both flow into the outlet channel 134 as shown in
The first flow channel 140 includes walls 144 and the second flow channel 142 includes walls 146. In one embodiment, a first portion of the dry anticoagulant powder 120 is deposited on walls 144 and a second portion of the dry anticoagulant powder 120 is deposited on walls 146. For example, in one embodiment, a first portion of the dry anticoagulant powder 120 is deposited on an interior surface 148 of the housing 114, e.g., an interior surface of wall 144, and a second portion of the dry anticoagulant powder 120 is deposited on an interior surface 148 of the housing 114, e.g., an interior surface of wall 146.
Referring to
In one embodiment, the specimen mixing and transfer device 100 includes a mixing element 115 disposed within the housing 114. For example, a portion of the mixing chamber 136 may also include obstacles or mixing promoters 150 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the dry anticoagulant powder 120. In some embodiments, a portion of the first flow channel 140 and a portion of the second flow channel 142 may include obstacles or mixing promoters 150 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the dry anticoagulant powder 120.
Referring to
With the blood sample received within the inlet channel 132, a first portion 152 of the blood sample flows to the first flow channel 140 and a second portion 154 of the blood sample flows to the second flow channel 142. The first flow channel 140 provides a first flow path for the first portion 152 of the blood sample and the second flow channel 142 provides a second flow path for the second portion 154 of the blood sample.
With the first portion 152 of the blood sample received within the first flow channel 140, the first portion 152 of the blood sample mixes with a first portion of the dry anticoagulant powder 120 deposited on the walls 144 of the first flow channel 140. The first flow channel 140 may also include obstacles or mixing promoters 150 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the first portion of the dry anticoagulant powder 120. After mixing, the first portion 152 of the blood sample and the first portion of the dry anticoagulant powder 120, i.e., a stabilized blood sample, travel to the outlet channel 134.
With the second portion 154 of the blood sample received within the second flow channel 142, the second portion 154 of the blood sample mixes with a second portion of the dry anticoagulant powder 120 deposited on the walls 146 of the second flow channel 142. The second flow channel 142 may also include obstacles or mixing promoters 150 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the second portion of the dry anticoagulant powder 120. After mixing, the second portion 154 of the blood sample and the second portion of the dry anticoagulant powder 120, i.e., a stabilized blood sample, travel to the outlet channel 134.
In other embodiments, other portions of the specimen mixing and transfer device 100 may also include obstacles or mixing promoters 150 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the dry anticoagulant powder 120.
The housing 214 includes a first end 222, a second end 224, and a sidewall 226 extending between the first end 222 and the second end 224. In one embodiment, the first end 222 includes an inlet 228 and the second end 224 includes an outlet 230.
Referring to
Referring to
In one embodiment, the specimen mixing and transfer device 200 includes a mixing element 215 disposed within the housing 214. In one embodiment, the mixing element 215 includes a plurality of posts 270. For example, the mixing chamber 236 may include a plurality of posts 270 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the dry anticoagulant powder 220.
Referring to
With the blood sample received within the inlet channel 232, the blood sample flows into the mixing chamber 236. As the blood sample flows into the mixing chamber 236, the blood sample mixes with the dry anticoagulant powder 220 deposited on an interior surface 260 of the housing 214. The mixing chamber 236 may include the plurality of posts 270 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the dry anticoagulant powder 220. After mixing, the blood sample and the dry anticoagulant powder 220, i.e., a stabilized blood sample, travel to the outlet channel 234.
In other embodiments, other portions of the specimen mixing and transfer device 200 may also include mixing elements 215 that interfere with the flow path of the blood sample thereby promoting mixing between the blood sample and the dry anticoagulant powder 220.
Referring to
In one embodiment, the material 502 is an open cell foam. For example, the material 502 is a soft deformable open cell foam that is inert to blood. In one embodiment, the open cell foam may be a melamine foam, such as Basotect® foam commercially available from BASF. In another embodiment, the open cell foam may consist of a formaldehyde-melamine-sodium bisulfite copolymer. The open cell foam may be a flexible, hydrophilic open cell foam that is resistant to heat and many organic solvents. In one embodiment, the open cell foam may be a sponge material.
Referring to
In one embodiment, the syringe assembly 500 includes a syringe barrel 506 having a first end 508, a second end 510, and a sidewall 512 extending therebetween and defining an interior 514. Referring to
In one embodiment, the syringe assembly 500 includes a plunger rod 516 and a stopper 518. The plunger rod 516 includes a first end 520 and a second end 522. The stopper 518 is engaged with the second end 522 of the plunger rod 516 and is slidably disposed within the interior 514 of the syringe barrel 506. The stopper 518 is sized relative to the interior 514 of the syringe barrel 506 to provide sealing engagement with the sidewall 512 of the syringe barrel 506.
The open cell foam material 502 is placed in the syringe barrel 506 for mixing and stabilizing blood. The blood gets collected in the syringe barrel 506 with the open cell foam material 502 embedded inside the syringe barrel 506. The stabilized blood can then be dispensed for analysis. In one embodiment, the syringe assembly 500 is an arterial blood gas syringe and the stabilized blood can be dispensed for blood gas analysis.
In one embodiment, the syringe assembly 500 acts as a flow-through chamber for the effective mixing of a blood sample with the dry anticoagulant powder 504 within the open cell foam material 502. In other embodiments, the open cell foam material 502 may contain other dry substances. The effective mixing is achieved by passing the blood sample through the open cell foam material 502 having the dry anticoagulant powder 504 distributed throughout its microstructure.
Referring to
In one embodiment, the line 604 includes an open cell foam material 612 having a dry anticoagulant powder 614 therein. The anticoagulant can be loaded into the open cell foam material 612 having pores, as described above. The open cell foam material 612 is disposed within the line 604. The line 604 includes a first end 616 and a second end 618.
In one embodiment, the syringe assembly 602 includes a syringe barrel 620 and a sidewall 622 defining an interior 624. Referring to
The open cell foam material 612 is placed in the line 604 for mixing and stabilizing blood. In one embodiment, the blood 608 is transferred from the container 606 to the syringe barrel 620 via the line 604. For example, a blood sample, e.g., blood 608, passes through the line 604 with the open cell foam material 612 embedded inside the line 604 as the blood gets collected into the syringe barrel 620. In this manner, the blood 608 is stabilized before entering the syringe barrel 620. After the stabilized blood 608 is contained within the syringe barrel 620, the stabilized blood 608 can then be dispensed for analysis.
In one embodiment, the line 604 acts as a flow-through chamber for the effective mixing of a blood sample with the dry anticoagulant powder 614 within the open cell foam material 612. In other embodiments, the open cell foam material 612 may contain other dry substances. The effective mixing is achieved by passing the blood sample through the open cell foam material 612 having the dry anticoagulant powder 614 distributed throughout its microstructure.
The present disclosure provides a material that includes pores and has a dry anticoagulant powder within the pores of the material, as described above. In one embodiment, the material is a sponge material. In other embodiments, the material is an open cell foam. In one embodiment, the open cell foam is treated with an anticoagulant, as described in detail above, to form a dry anticoagulant powder finely distributed throughout the pores of the material.
The present disclosure provides different applications and embodiments of the material. For example, in one embodiment, a specimen mixing and transfer device of the present disclosure is adapted to receive a sample. The specimen mixing and transfer device includes a housing, a material including pores that is disposed within the housing, and a dry anticoagulant powder within the pores of the material. In one embodiment, the material is a sponge material. In other embodiments, the material is an open cell foam. In one embodiment, the open cell foam is treated with an anticoagulant to form a dry anticoagulant powder finely distributed throughout the pores of the material. A blood sample may be received within the specimen mixing and transfer device. The blood sample is exposed to and mixes with the anticoagulant powder while passing through the material.
A specimen mixing and transfer device of the present disclosure offers uniform and passive blood mixing with an anticoagulant under flow-through conditions. A specimen mixing and transfer device of the present disclosure could catch blood clots or other contaminants within the microstructure of the material and prevent them from being dispensed into a diagnostic sample port. A specimen mixing and transfer device of the present disclosure enables a simple, low-cost design for passive flow-through blood stabilization. A specimen mixing and transfer device of the present disclosure enables precisely controlled loading of an anticoagulant into the material by soaking it with an anticoagulant and water solution and then drying the material to form a finely distributed dry anticoagulant powder throughout the pores of the material.
A specimen mixing and transfer device of the present disclosure may provide an effective passive blood mixing solution for applications wherein blood flows through a line. Such a specimen mixing and transfer device is useful for small blood volumes, e.g., less than 50 μL, or less than 500 μL, and/or where inertial, e.g., gravity based, forces are ineffective for bulk manual mixing by flipping back and forth a blood collection container such as is required for vacuum tubes.
In other embodiments of the present disclosure, the material can be utilized with a specimen mixing and transfer system or a syringe assembly, as described above.
While this disclosure has been described as having exemplary designs, the present disclosure can be further modified within the spirit and scope of this disclosure. This application is therefore intended to cover any variations, uses, or adaptations, of the disclosure using its general principles. Further, this application is intended to cover such departures from the present disclosure as come within known or customary practice in the art to which this disclosure pertains and which fall within the limits of the appended claims.
This application claims priority to U.S. Provisional Application Ser. No. 62/063,536, entitled “Blood Sample Management Using Open Cell Foam” filed Oct. 14, 2014, and U.S. Provisional Application Ser. No. 62/207,618, entitled “Blood Sample Management Using Open Cell Foam” filed Aug. 20, 2015, the entire disclosures of each of which are herein incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
3626929 | Sanz | Dec 1971 | A |
3819913 | Carter et al. | Jun 1974 | A |
3916205 | Kleinerman | Oct 1975 | A |
3963350 | Watanabe et al. | Jun 1976 | A |
4088448 | Lilja et al. | May 1978 | A |
4125828 | Resnick et al. | Nov 1978 | A |
4133304 | Bailey | Jan 1979 | A |
4133873 | Noller | Jan 1979 | A |
4337222 | Kitajima et al. | Jun 1982 | A |
4501496 | Griffin | Feb 1985 | A |
4703761 | Rathbone et al. | Nov 1987 | A |
4727020 | Recktenwald | Feb 1988 | A |
4751188 | Valet | Jun 1988 | A |
4857735 | Noller | Aug 1989 | A |
4959305 | Woodrum | Sep 1990 | A |
5014718 | Mitchen | May 1991 | A |
5053626 | Tillotson | Oct 1991 | A |
5073857 | Peters et al. | Dec 1991 | A |
5102625 | Milo | Apr 1992 | A |
5134662 | Bacus et al. | Jul 1992 | A |
5159642 | Kosaka | Oct 1992 | A |
5187749 | Sugimoto et al. | Feb 1993 | A |
5196709 | Berndt et al. | Mar 1993 | A |
5200152 | Brown | Apr 1993 | A |
5294799 | Aslund et al. | Mar 1994 | A |
5332905 | Brooker et al. | Jul 1994 | A |
5348859 | Brunhouse et al. | Sep 1994 | A |
5385539 | Maynard | Jan 1995 | A |
5489771 | Beach et al. | Feb 1996 | A |
5491343 | Brooker | Feb 1996 | A |
5528045 | Hoffman et al. | Jun 1996 | A |
5547849 | Baer et al. | Aug 1996 | A |
5556764 | Sizto et al. | Sep 1996 | A |
5592291 | Iida | Jan 1997 | A |
5599668 | Stimpson et al. | Feb 1997 | A |
5627037 | Ward et al. | May 1997 | A |
5661558 | Nogami et al. | Aug 1997 | A |
5674457 | Williamsson et al. | Oct 1997 | A |
5675155 | Pentoney, Jr. et al. | Oct 1997 | A |
5681529 | Taguchi et al. | Oct 1997 | A |
5692503 | Kuenstner | Dec 1997 | A |
5732150 | Zhou et al. | Mar 1998 | A |
5733721 | Hemstreet, III et al. | Mar 1998 | A |
5770158 | Eischen et al. | Jun 1998 | A |
5773301 | Ziegler | Jun 1998 | A |
5851835 | Groner | Dec 1998 | A |
5890828 | Gueret | Apr 1999 | A |
5898487 | Hage | Apr 1999 | A |
5933233 | Günther | Aug 1999 | A |
5938439 | Mertins et al. | Aug 1999 | A |
6043880 | Andrews et al. | Mar 2000 | A |
6064474 | Lee et al. | May 2000 | A |
6064897 | Lindberg et al. | May 2000 | A |
6094592 | Yorkey et al. | Jul 2000 | A |
6103197 | Werner | Aug 2000 | A |
6154282 | Lilge et al. | Nov 2000 | A |
6159740 | Hudson et al. | Dec 2000 | A |
6181418 | Palumbo et al. | Jan 2001 | B1 |
6187592 | Gourley | Feb 2001 | B1 |
6214629 | Freitag et al. | Apr 2001 | B1 |
6226347 | Golenhoffen | May 2001 | B1 |
6262798 | Shepherd et al. | Jul 2001 | B1 |
6294094 | Muller et al. | Sep 2001 | B1 |
6305804 | Rice et al. | Oct 2001 | B1 |
6342376 | Kozian et al. | Jan 2002 | B1 |
6350613 | Wardlaw et al. | Feb 2002 | B1 |
6410341 | Freitag et al. | Jun 2002 | B1 |
6448018 | Nakayana et al. | Sep 2002 | B1 |
6453060 | Riley et al. | Sep 2002 | B1 |
6477394 | Rice et al. | Nov 2002 | B2 |
6479299 | Parce et al. | Nov 2002 | B1 |
6493567 | Krivitski et al. | Dec 2002 | B1 |
6519025 | Shepherd et al. | Feb 2003 | B2 |
6563585 | Rao et al. | May 2003 | B1 |
6594075 | Kanao et al. | Jul 2003 | B1 |
6611320 | Lindberg et al. | Aug 2003 | B1 |
6612111 | Hodges et al. | Sep 2003 | B1 |
6638769 | Lilja et al. | Oct 2003 | B2 |
6665060 | Zahniser et al. | Dec 2003 | B1 |
6696240 | Kloepfer et al. | Feb 2004 | B1 |
6716588 | Sammak et al. | Apr 2004 | B2 |
6723290 | Wardlaw | Apr 2004 | B1 |
6740527 | Wong et al. | May 2004 | B1 |
6825921 | Modlin et al. | Nov 2004 | B1 |
6828567 | Amirkhanian et al. | Dec 2004 | B2 |
6831733 | Pettersson et al. | Dec 2004 | B2 |
6858400 | Bristow | Feb 2005 | B2 |
6862534 | Sterling et al. | Mar 2005 | B2 |
6869405 | Marsden | Mar 2005 | B2 |
6869570 | Wardlaw | Mar 2005 | B2 |
6898458 | Zeng et al. | May 2005 | B2 |
6960165 | Ueno et al. | Nov 2005 | B2 |
6985224 | Hart | Jan 2006 | B2 |
6999173 | Kleinfeld et al. | Feb 2006 | B2 |
7075628 | Shepherd et al. | Jul 2006 | B2 |
7094562 | Bittner | Aug 2006 | B2 |
7096124 | Sterling et al. | Aug 2006 | B2 |
7115841 | Zeng et al. | Oct 2006 | B2 |
7133545 | Douglass et al. | Nov 2006 | B2 |
7139073 | Terada | Nov 2006 | B1 |
7146372 | Bacus et al. | Dec 2006 | B2 |
7149332 | Bacus et al. | Dec 2006 | B2 |
7271912 | Sterling et al. | Sep 2007 | B2 |
7279134 | Chan et al. | Oct 2007 | B2 |
7303922 | Jeng et al. | Dec 2007 | B2 |
7319894 | Higgins | Jan 2008 | B2 |
7324674 | Ozawa et al. | Jan 2008 | B2 |
7378054 | Karmali | May 2008 | B2 |
7420660 | Muller et al. | Sep 2008 | B2 |
7426407 | Higgins | Sep 2008 | B2 |
7477382 | Grey et al. | Jan 2009 | B2 |
7500569 | Manoussakis et al. | Mar 2009 | B2 |
7515268 | Ayliffe et al. | Apr 2009 | B1 |
7518727 | Pentoney, Jr. et al. | Apr 2009 | B2 |
7539335 | Fukuyama | May 2009 | B2 |
7560073 | Peters et al. | Jul 2009 | B1 |
7625712 | Paul et al. | Dec 2009 | B2 |
7630063 | Padmanabhan et al. | Dec 2009 | B2 |
7674598 | Paul et al. | Mar 2010 | B2 |
7738094 | Goldberg | Jun 2010 | B2 |
7762946 | Sugimoto | Jul 2010 | B2 |
7781226 | McDevitt et al. | Aug 2010 | B2 |
7790464 | Tarasev | Sep 2010 | B2 |
7816135 | Goldberg | Oct 2010 | B2 |
7826728 | Konno et al. | Nov 2010 | B2 |
7854891 | Yamamoto et al. | Dec 2010 | B2 |
7892551 | Glencross | Feb 2011 | B2 |
7903241 | Wardlaw et al. | Mar 2011 | B2 |
7952692 | Primack et al. | May 2011 | B2 |
8009894 | Lindberg et al. | Aug 2011 | B2 |
8125623 | Munger et al. | Feb 2012 | B2 |
8224058 | Lindberg et al. | Jul 2012 | B2 |
8244021 | Lett et al. | Aug 2012 | B2 |
8306594 | Paseman et al. | Nov 2012 | B2 |
8353848 | Long et al. | Jan 2013 | B2 |
8358405 | Kitamura et al. | Jan 2013 | B2 |
8377398 | McDevitt et al. | Feb 2013 | B2 |
8406859 | Zuzak et al. | Mar 2013 | B2 |
8483789 | Higgins | Jul 2013 | B2 |
8488903 | Higuchi | Jul 2013 | B2 |
8541227 | Christensen et al. | Sep 2013 | B2 |
8630016 | Swenson et al. | Jan 2014 | B2 |
8753890 | Lalpuria et al. | Jun 2014 | B2 |
9693723 | Ivosevic et al. | Jul 2017 | B2 |
20020143298 | Marsden | Oct 2002 | A1 |
20020164825 | Chen | Nov 2002 | A1 |
20030123047 | Pettersson et al. | Jul 2003 | A1 |
20030152927 | Jakobsen et al. | Aug 2003 | A1 |
20030170613 | Straus | Sep 2003 | A1 |
20030206828 | Bell | Nov 2003 | A1 |
20030230728 | Dai et al. | Dec 2003 | A1 |
20040048395 | Lee et al. | Mar 2004 | A1 |
20040224329 | Gjerde et al. | Nov 2004 | A1 |
20050054949 | McKinnon et al. | Mar 2005 | A1 |
20050139547 | Manoussakis et al. | Jun 2005 | A1 |
20050142565 | Samper et al. | Jun 2005 | A1 |
20050190058 | Call | Sep 2005 | A1 |
20050232813 | Karmali | Oct 2005 | A1 |
20060020531 | Veeneman et al. | Jan 2006 | A1 |
20060024756 | Tibbe et al. | Feb 2006 | A1 |
20060060531 | Coville et al. | Mar 2006 | A1 |
20060241495 | Kurtz | Oct 2006 | A1 |
20060252079 | Oldham et al. | Nov 2006 | A1 |
20070132994 | Kobayashi et al. | Jun 2007 | A1 |
20070178009 | Sakaino et al. | Aug 2007 | A1 |
20070196813 | Franzen | Aug 2007 | A1 |
20080047908 | Sekine | Feb 2008 | A1 |
20080190220 | Backes et al. | Aug 2008 | A1 |
20080203319 | Pentoney et al. | Aug 2008 | A1 |
20080268469 | Srienc et al. | Oct 2008 | A1 |
20090024060 | Darrigrand et al. | Jan 2009 | A1 |
20090075324 | Pettersson | Mar 2009 | A1 |
20090107903 | Dassa | Apr 2009 | A1 |
20090130646 | Fletcher et al. | May 2009 | A1 |
20090173685 | Imai et al. | Jul 2009 | A1 |
20090181411 | Battrell et al. | Jul 2009 | A1 |
20090259145 | Bartfeld | Oct 2009 | A1 |
20100285520 | Halverson et al. | Nov 2010 | A1 |
20100291599 | Tague, Jr. et al. | Nov 2010 | A1 |
20100294950 | Kitamura et al. | Nov 2010 | A1 |
20100314461 | Gruenbacher et al. | Dec 2010 | A1 |
20110106046 | Hiranuma et al. | May 2011 | A1 |
20110118139 | Mehta et al. | May 2011 | A1 |
20110159457 | Offermann | Jun 2011 | A1 |
20110159533 | Karkouche | Jun 2011 | A1 |
20110244581 | Nikonorov et al. | Oct 2011 | A1 |
20120016265 | Peterson et al. | Jan 2012 | A1 |
20120016307 | Burkholz et al. | Jan 2012 | A1 |
20120123297 | Brancazio | May 2012 | A1 |
20130045529 | Goldberg et al. | Feb 2013 | A1 |
20130076019 | Takemoto | Mar 2013 | A1 |
20130162990 | Kobayashi et al. | Jun 2013 | A1 |
20140073990 | Holmes et al. | Mar 2014 | A1 |
20140093896 | Mongale et al. | Apr 2014 | A1 |
20140200154 | Sugarman et al. | Jul 2014 | A1 |
20140269160 | Chee Mun | Sep 2014 | A1 |
20150112302 | Chattaraj | Apr 2015 | A1 |
20150125882 | Bomheimer et al. | May 2015 | A1 |
20150125883 | Gordon et al. | May 2015 | A1 |
20150132789 | Bomheimer et al. | May 2015 | A1 |
20160100783 | Ivosevic et al. | Apr 2016 | A1 |
Number | Date | Country |
---|---|---|
1365987 | Aug 2002 | CN |
101036591 | Sep 2007 | CN |
102119017 | Jul 2011 | CN |
202141619 | Feb 2012 | CN |
103068307 | Apr 2013 | CN |
202928839 | May 2013 | CN |
203677610 | Jul 2014 | CN |
203785945 | Aug 2014 | CN |
205181357 | Apr 2016 | CN |
205317561 | Jun 2016 | CN |
0219053 | Apr 1987 | EP |
0545500 | Jun 1993 | EP |
0663070 | Jul 1995 | EP |
0681177 | Nov 1995 | EP |
0681177 | Nov 1995 | EP |
0737855 | Oct 1996 | EP |
0744600 | Nov 1996 | EP |
0788615 | Aug 1997 | EP |
0788615 | Aug 1997 | EP |
0800074 | Oct 1997 | EP |
0800074 | Oct 1997 | EP |
0818682 | Jan 1998 | EP |
0818682 | Jan 1998 | EP |
0821784 | Nov 1998 | EP |
0959346 | Nov 1999 | EP |
0969279 | Jan 2000 | EP |
0969279 | Jan 2000 | EP |
0809807 | Jul 2002 | EP |
1324021 | Jul 2003 | EP |
1324021 | Jul 2003 | EP |
1347702 | Oct 2003 | EP |
1456649 | Jun 2006 | EP |
1698883 | Sep 2006 | EP |
1698883 | Sep 2006 | EP |
1701150 | Sep 2006 | EP |
1767935 | Mar 2007 | EP |
1924195 | May 2008 | EP |
1990638 | Nov 2008 | EP |
2016390 | Jan 2009 | EP |
2041549 | Apr 2009 | EP |
2083687 | Aug 2009 | EP |
1405073 | Mar 2010 | EP |
2232442 | Sep 2010 | EP |
2298407 | Mar 2011 | EP |
2016390 | Apr 2013 | EP |
2586370 | May 2013 | EP |
2605020 | Jun 2013 | EP |
1558934 | Jul 2013 | EP |
2676606 | Dec 2013 | EP |
1595388 | Aug 1981 | GB |
H10323341 | Dec 1998 | JP |
11318871 | Nov 1999 | JP |
200074906 | Mar 2000 | JP |
2000176006 | Jun 2000 | JP |
200188098 | Apr 2001 | JP |
2001324500 | Nov 2001 | JP |
2002506208 | Feb 2002 | JP |
2002516982 | Jun 2002 | JP |
200319126 | Jan 2003 | JP |
200517280 | Jan 2005 | JP |
200517281 | Jan 2005 | JP |
2005006821 | Jan 2005 | JP |
2005524841 | Aug 2005 | JP |
2006208188 | Aug 2006 | JP |
2006317285 | Nov 2006 | JP |
2007-24522 | Feb 2007 | JP |
2007024522 | Feb 2007 | JP |
2007155441 | Jun 2007 | JP |
2007518978 | Jul 2007 | JP |
2008525768 | Jul 2008 | JP |
4255556 | Feb 2009 | JP |
2009525819 | Jul 2009 | JP |
2011133235 | Jul 2011 | JP |
2011529573 | Dec 2011 | JP |
2012132879 | Jul 2012 | JP |
2012137493 | Jul 2012 | JP |
2013096797 | May 2013 | JP |
2013524219 | Jun 2013 | JP |
2013545114 | Dec 2013 | JP |
6909366 | Jan 1970 | NL |
9920998 | Apr 1999 | WO |
9945384 | Sep 1999 | WO |
0028297 | May 2000 | WO |
0029847 | May 2000 | WO |
0244729 | Jun 2002 | WO |
0250518 | Jun 2002 | WO |
03036290 | May 2003 | WO |
2004100887 | Nov 2004 | WO |
2005100539 | Oct 2005 | WO |
2006047831 | May 2006 | WO |
2006096126 | Sep 2006 | WO |
2006119368 | Nov 2006 | WO |
2006124756 | Nov 2006 | WO |
2007012975 | Feb 2007 | WO |
2007033318 | Mar 2007 | WO |
2007051861 | May 2007 | WO |
2007111555 | Oct 2007 | WO |
2007129948 | Nov 2007 | WO |
2007145328 | Dec 2007 | WO |
2008002462 | Jan 2008 | WO |
2008010761 | Jan 2008 | WO |
2008037068 | Apr 2008 | WO |
2008103992 | Aug 2008 | WO |
2009091318 | Jul 2009 | WO |
2009093306 | Jul 2009 | WO |
2009155612 | Dec 2009 | WO |
WO20090155612 | Dec 2009 | WO |
2010003518 | Jan 2010 | WO |
2010085658 | Jul 2010 | WO |
2011133540 | Oct 2011 | WO |
2012117648 | Sep 2012 | WO |
2013075031 | May 2013 | WO |
2013128177 | Sep 2013 | WO |
Number | Date | Country | |
---|---|---|---|
20160103046 A1 | Apr 2016 | US |
Number | Date | Country | |
---|---|---|---|
62063536 | Oct 2014 | US | |
62207618 | Aug 2015 | US |